New York, NY -- (SBWIRE) -- 12/05/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Yahoo! Inc (NASDAQ:YHOO), Geron Corporation (NASDAQ:GERN), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), Advanced Cell Technology, Inc (OTCMKTS:ACTC)
Yahoo! Inc (NASDAQ:YHOO) showed a volume of 26.13 shares by the end of last trade whereas the average volume of the stock remained 16.74 million shares. The stock opened the session at $36.47 but then moved to $38.13. At that price, the stock showed a positive performance of 4.29%. Yahoo! Inc. (Yahoo!) is a digital media company. Through the Company’s technology and insights, Yahoo! delivers digital content and experiences, across devices and globally. The Company provides online properties and services (Yahoo! Properties) to users, as well as a range of marketing services designed to reach and connect with those users on Yahoo! and through a distribution network of third-party entities (Affiliates).
Will YHOO Continue To Move Higher? Find Out Here
Geron Corporation (NASDAQ:GERN) opened the session at $5.70 and closed the session at $5.74. The stock showed a positive performance of 4.74% in previous trading session. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase.
For How Long GERN will fight for Profitability? Read This Trend Analysis report
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) opened the session at $1.66 and closed the session at $1.83. The stock showed a positive performance of 10.24% in previous trading session. Traded with volume of 2.72 million shares in the prior session and the average volume of the stock remained 1.52 million shares. The beta of the stock remained 0.60. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc.
Why Should Investors Buy NAVB After The Recent Gain? Just Go Here and Find Out
Advanced Cell Technology, Inc (OTCMKTS:ACTC) the stock decreased -0.49% and finished the session at $0.0607. Traded with volume of 5.62 million shares in the prior session and the average volume of the stock remained 4.70 million shares. The beta of the stock remained -3.99. Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research.
Will ACTC Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)